NEW YORK, March 16, 2011 /PRNewswire/ -- Get content from Novo Nordisk A/S at:
Novo Nordisk announced on March 15 that the Chinese State Food and Drug Administration (SFDA) has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue approved in China, developed for the treatment of type 2 diabetes in adults. Victoza® is indicated as an add-on to metformin or sulfonylurea (SU) in people with type 2 diabetes. "Diabetes is a rapidly growing disease in China, and Victoza® offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycaemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents." Novo Nordisk expects to launch Victoza® in China in the second half of 2011. Available video includes Novo Nordisk headquarters shots, Victoza production and Victoza R&D shots.
thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE, ZDF and a lot more.
Registered journalists can preview and download video, audio, text, graphics and photos at http://www.thenewsmarket.com.
If not already registered, please take a moment to sign up - registration is quick, easy and free: http://www.thenewsmarket.com/registration
We are always happy to receive your feedback, suggestions or enquiries. Email us at email@example.com
Story Id: 22069
Copyright©2010 PR Newswire.
All rights reserved